Financings in Brief: Gamera Bioscience
This article was originally published in The Gray Sheet
Executive SummaryGamera Bioscience: Private placement financing of $4.5 mil. is completed with venture syndicate consisting of Spray Venture Fund, Advent International and Bessemer Venture Partners. Funding will go towards development of the firm's LabCD System platform technology. The system, which incorporates "a modified CD player and disposable compact discs" and is designed to perform "sophisticated laboratory tests at the point-of-care," is expected to be "the first portable, automated device able to perform the full spectrum of analytical tests, including cell counting, DNA analysis, immunoassays and clinical chemistries," Gamera states...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.